Estimating the Real-World Cost of Diabetes Mellitus in the United States During an 8-Year Period Using 2 Cost Methodologies.

导出 LinkOut

翻译打印收藏纠错

作者： Vincent J,Willey ^[1] ; Sheldon,Kong ^[2] ; Bingcao,Wu ^[3] ; Amit,Raval ^[3] ; Todd,Hobbs ^[4] ; Andrea,Windsheimer ^[5] ; Gaurav,Deshpande ^[6] ; Ozgur,Tunceli ^[3] ; Brian,Sakurada ^[5] ; Jonathan R,Bouchard ^[5]

作者单位： Staff Vice President, HealthCore, Wilmington, DE. ^[1] Executive Director, Health Economics and Outcomes Research, Novo Nordisk, Plainsboro, NJ. ^[2] Employees of HealthCore at the time of the study. ^[3] Vice President and Chief Medical Officer, Diabetes & Obesity, Novo Nordisk. ^[4] Employees of Novo Nordisk at the time of the study. ^[5] Senior Researcher, HealthCore. ^[6]

关键词 cost projection cost-estimation method diabetes disease prevalence healthcare utilization prevalence type 1 diabetes type 2 diabetes

PMID 30464797

发布时间 2022-03-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览11

American health & drug benefits

2018年11卷6期

310-318页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Estimating the Real-World Cost of Diabetes Mellitus in the United States During an 8-Year Period Using 2 Cost Methodologies.

American health & drug benefits

相似文献

American health & drug benefits

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Estimating the Real-World Cost of Diabetes Mellitus in the United States During an 8-Year Period Using 2 Cost Methodologies.

American health & drug benefits

相似文献

American health & drug benefits

相关期刊

检索历史清除